Agile Therapeutics, Inc.
AGRX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $20 | $11 | $4 | $1 |
| % Growth | 80% | 165.4% | 447.5% | – |
| Cost of Goods Sold | $9 | $7 | $11 | $0 |
| Gross Profit | $11 | $4 | -$7 | $0 |
| % Margin | 54.2% | 37.2% | -161.4% | 62.3% |
| R&D Expenses | $2 | $3 | $6 | $14 |
| G&A Expenses | $11 | $12 | $15 | $13 |
| SG&A Expenses | $28 | $42 | $58 | $36 |
| Sales & Mktg Exp. | $18 | $30 | $43 | $23 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30 | $45 | $64 | $50 |
| Operating Income | -$20 | -$41 | -$71 | -$49 |
| % Margin | -101.5% | -380.7% | -1,731.4% | -6,549.1% |
| Other Income/Exp. Net | $5 | $11 | -$0 | -$3 |
| Pre-Tax Income | -$14 | -$30 | -$75 | -$52 |
| Tax Expense | $0 | -$5 | $2 | $0 |
| Net Income | -$14 | -$25 | -$77 | -$55 |
| % Margin | -73.8% | -233.5% | -1,867.5% | -7,301.2% |
| EPS | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| % Growth | 88.6% | 99.9% | -4,786.8% | – |
| EPS Diluted | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $3 | $4 | $3 |
| Depreciation & Amortization | $0 | $2 | $2 | $0 |
| EBITDA | -$13 | -$25 | -$65 | -$48 |
| % Margin | -64.6% | -233.6% | -1,583.3% | -6,471% |